Treatment of Parkinson's disease in the advanced stage

Journal of Neural Transmission

Volumn 120, Issue 4, 2013, Pages 523-529

  Ossig, C ^a   Reichmann, H ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Advanced Parkinson's disease; Dyskinesia; Levodopa; Motor fluctuations

Indexed keywords

AMPHETAMINE; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA; METHAMPHETAMINE; MONOAMINE OXIDASE B INHIBITOR; PIRIBEDIL; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; TOLCAPONE;

ADD ON THERAPY; APRAXIA; BRAIN DEPTH STIMULATION; CONFERENCE PAPER; CONTINUOUS INFUSION; DAYTIME SOMNOLENCE; DIZZINESS; DRUG EFFICACY; DYSARTHRIA; DYSKINESIA; FATIGUE; HUMAN; KIDNEY DYSFUNCTION; LUNG EMBOLISM; MOTOR DYSFUNCTION; NAUSEA; OCULOMOTOR NERVE DISEASE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; SLEEP DISORDER; SUBTHALAMIC NUCLEUS; UNSPECIFIED SIDE EFFECT;

ANTIPARKINSON AGENTS; CARBIDOPA; DOPAMINE AGONISTS; DRUG COMBINATIONS; DYSKINESIAS; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84875741505     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1008-y     Document Type: Conference Paper

References (54)

1. Antonini A, Cilia R (2009) Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf 32(6):475-488. doi: 10.2165/00002018-200932060-00004
2. Antonini A, Colosimo C, Marconi R, Morgante L, Barone P (2008a) The PRIAMO study: background, methods and recruitment. Neurol Sci 29(2):61-65. doi: 10.1007/s10072-008-0863-z (Pubitemid 351696406)
3. Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, Pacchetti C, Zibetti M, Natuzzi F, Lopiano L, Nappi G, Pezzoli G (2008b) Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 5(3-4):244-246. doi: 10.1159/000113714 (Pubitemid 351347862)
4. Baizabal Carvallo JF, Mostile G, Almaguer M, Davidson A, Simpson R, Jankovic J (2012) Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg 90(5):300-306. doi: 10.1159/000338222
5. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24(11):1641-1649. doi: 10.1002/mds.22643
6. Benabid AL, Pollak P, Gross C, Hoffmann D, Benazzouz A, Gao DM, Laurent A, Gentil M, Perret J (1994) Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg 62(1-4):76-84
7. Bowron A (2004) Practical considerations in the use of apomorphine injectable. Neurology 62(6 Suppl 4):S32-S36
8. Charles PD, Van Blercom N, Krack P, Lee SL, Xie J, Besson G, Benabid AL, Pollak P (2002) Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 59(6):932-934
9. Deane KH, Spieker S, Clarke CE (2004) Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 4:CD004554. doi: 10.1002/14651858.CD004554.pub2
10. Deleu D, Hanssens Y, Northway MG (2004) Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 21(11):687-709 (Pubitemid 39273964)
11. Deuschl G, Herzog J, Kleiner-Fisman G, Kubu C, Lozano AM, Lyons KE, Rodriguez-Oroz MC, Tamma F, Troster AI, Vitek JL, Volkmann J, Voon V (2006) Deep brain stimulation: postoperative issues. Mov Disord 21(Suppl 14):S219-S237. doi: 10.1002/mds.20957 (Pubitemid 44028283)
12. Eggert K, Schrader C, Hahn M, Stamelou M, Russmann A, Dengler R, Oertel W, Odin P (2008) Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31(3):151-166. doi: 10.1097/wnf. 0b013e31814b113e (Pubitemid 351787111)
13. Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 252(Suppl 4):IV37-IV42. doi: 10.1007/s00415-005- 4008-5 (Pubitemid 41437719)
14. Frankel JP, Lees AJ, Kempster PA, Stern GM (1990) Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 53(2):96-101 (Pubitemid 20067654)
15. Grace AA, Bunney BS (1984) The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 4(11):2866-2876 (Pubitemid 15224431)
16. Grosset KA, Reid JL, Grosset DG (2005) Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord 20(11):1397-1404. doi: 10.1002/mds.20525 (Pubitemid 43072646)
17. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ (2009) Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 24(4):564-573. doi: 10.1002/mds.22402
18. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311(5985):467-469 (Pubitemid 14035453)
19. Hilker R, Antonini A, Odin P (2011) What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? J Neural Transm 118(6):907-914. doi: 10.1007/s00702-010-0555-8
20. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61(7):1044-1053. doi: 10.1001/archneur.61.7.1044 (Pubitemid 38915945)
21. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR (2009) Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24(10):1468-1474. doi: 10.1002/mds.22596
22. Kostic V, Przedborski S, Flaster E, Sternic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 41(2(Pt 1)):202-205
23. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349(20):1925-1934. doi: 10.1056/NEJMoa035275 (Pubitemid 37409709)
24. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 339(16):1105-1111. doi: 10.1056/ NEJM199810153391603 (Pubitemid 28465758)
25. Lyons KE, Wilkinson SB, Overman J, Pahwa R (2004) Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology 63(4):612-616 (Pubitemid 39100813)
26. Manson AJ, Hanagasi H, Turner K, Patsalos PN, Carey P, Ratnaraj N, Lees AJ (2001) Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 124(Pt 2):331-340 (Pubitemid 32142405)
27. Morgante L, Basile G, Epifanio A, Spina E, Antonini A, Stocchi F, Di Rosa E, Martino G, Marconi R, La Spina P, Nicita-Mauro V, Di Rosa AE (2004) Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. Arch Gerontol Geriatr Suppl 9:291-296. doi: 10.1016/j.archger.2004.04.039 (Pubitemid 38822878)
28. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN (1989) Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 25(5):523-526. doi: 10.1002/ana.410250521 (Pubitemid 19136689)
29. Neef C, van Laar T (1999) Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 37(3):257-271 (Pubitemid 29452757)
30. Obeso JA, Grandas F, Herrero MT, Horowski R (1994) The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 6(6):889-897 (Pubitemid 24185313)
31. Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, Beute GN, van Vugt JP, Lenders MW, Contarino MF, Mink MS, Bour LJ, van den Munckhof P, Schmand BA, de Haan RJ, Schuurman PR, de Bie RM (2013) Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 12(1):37-44. doi: 10.1016/S1474-4422(12)70264-8
32. Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic J et al (1994) A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 9(1):40-47. doi: 10.1002/mds.870090107 (Pubitemid 24022613)
33. Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19(9):997-1005. doi: 10.1002/mds.20243 (Pubitemid 39302831)
34. Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5(8):677-687. doi: 10.1016/S1474-4422(06)70521-X (Pubitemid 44081890)
35. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E (2009) A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361(13):1268-1278. doi: 10.1056/NEJMoa0809335
36. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68(14):1108-1115. doi: 10.1212/01.wnl.0000258660.74391.c1 (Pubitemid 46559844)
37. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328(3):176-183 (Pubitemid 23021504)
38. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42(5):747-755. doi: 10.1002/ana.410420511 (Pubitemid 27481547)
39. Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62(2):241-248 (Pubitemid 40204745)
40. Pinter MM, Pogarell O, Oertel WH (1999) Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 66(4):436-441 (Pubitemid 29145676)
41. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484-1491. doi: 10.1056/NEJM200005183422004 (Pubitemid 30318272)
42. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463):947-954. doi: 10.1016/S0140-6736(05)71083-7 (Pubitemid 41071428)
43. Reuter I, Ellis CM, Ray Chaudhuri K (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 100(3):163-167 (Pubitemid 29376827)
44. Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease. a community-based study. Brain 123(Pt 11):2297-2305
45. Stocchi F (2005) Pathological gambling in Parkinson's disease. Lancet Neurol 4(10):590-592. doi: 10.1016/S1474-4422(05)70177-0 (Pubitemid 41317291)
46. Stocchi F, Rabey JM (2011) Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Eur J Neurol 18(12):1373-1378. doi: 10.1111/j.1468-1331.2011.03512.x
47. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S (2001) Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 22(1):93-94 (Pubitemid 32622278)
48. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18-27. doi: 10.1002/ana.22060
49. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR (2011) Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90-99. doi: 10.1002/mds.23441
50. Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM (2003) Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. J Neurochem 87(5):1284-1295 (Pubitemid 37485084)
51. Voges J, Hilker R, Botzel K, Kiening KL, Kloss M, Kupsch A, Schnitzler A, Schneider GH, Steude U, Deuschl G, Pinsker MO (2007) Thirty days complication rate following surgery performed for deep-brain-stimulation. Mov Disord 22(10):1486-1489. doi: 10.1002/mds.21481 (Pubitemid 47280638)
52. Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schupbach M, D'Ambrosia J, Thobois S, Tamma F, Herzog J, Speelman JD, Samanta J, Kubu C, Rossignol H, Poon YY, Saint-Cyr JA, Ardouin C, Moro E (2008) A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 131(Pt 10):2720-2728. doi: 10.1093/brain/awn214
53. Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL (2010) Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 25(7):858-866. doi: 10.1002/mds.22890
54. Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ (2012) Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology 79(1):55-65. doi: 10.1212/WNL.0b013e31825dcdc1